Physician profile
Joseph Binns
NPI 1326049511
$13,573.26
in general payments reported to CMS, 2019-2025
39 companies · $7,354 in 2025
The $7,354 reported for 2025 was more than what 92% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,459 · 2020: $535 · 2021: $169 · 2022: $1,005 · 2023: $1,390 · 2024: $1,661 · 2025: $7,354.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Acquisitions: $5,685 · Food and Beverage: $4,680 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20.00 · Grant: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Acquisitions | $5,685.10 |
| Food and Beverage | $4,679.85 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20.00 |
| Grant | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $5,685.10 | 2025 | |
| Abbvie INC. | $2,060.26 | 2019-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $974.34 | 2019-2025 | Tremfya, Stelara, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $873.06 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Pfizer INC. | $470.61 | 2019-2025 | |
| Ferring Pharmaceuticals INC. | $322.19 | 2019-2024 | Rebyota, Cimzia |
| Takeda Pharmaceuticals U.S.A., INC. | $303.16 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Qol Medical, LLC | $301.84 | 2019-2025 | Sucraid, Sucraid |
| Janssen Scientific Affairs, LLC | $293.06 | 2022-2024 | Tremfya, Stelara |
| Genzyme Corporation | $288.78 | 2022-2025 | |
| Lilly USA, LLC | $236.31 | 2024-2025 | Omvoh, Zepbound |
| Gilead Sciences, INC. | $220.65 | 2023-2025 | Epclusa |
| Celgene Corporation | $158.92 | 2022-2024 | Zeposia |
| Madrigal Pharmaceuticals | $155.72 | 2024-2025 | Resmetirom, Rezdiffra |
| Braintree Laboratories, INC. | $132.74 | 2019-2024 | Sutab, Suflave |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Binns listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.